Cyclosporine Market By Product Formulation (Oral Cyclosporine, Ophthalmic Cyclosporine, Injectable/Intravenous Cyclosporine); By Therapeutic Application (Organ Transplantation, Ophthalmic Disorders, Autoimmune Diseases, Psoriasis and Other Dermatological Applications); By Brand Type (Generic Cyclosporine, Branded Cyclosporine); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Cyclosporine Market: Transplant Care Sustains Revenue as Ophthalmic Therapies Expand – (Updated On: 1st-Oct-2026)

The Global Cyclosporine Market was estimated at USD 2.80 billion in 2025 and is projected to reach USD 4.04 billion by 2032, registering a CAGR of 5.30% during 2026–2032.

 

Cyclosporine is a calcineurin-inhibitor immunosuppressant that suppresses T-lymphocyte activity by reducing cytokine signaling. Its established systemic uses include prevention of rejection after kidney, liver, and heart transplantation, severe active rheumatoid arthritis that has responded inadequately to methotrexate, and severe recalcitrant plaque psoriasis.

 

Cyclosporine has a substantial prescription base in the United States. Approximately 3.23 million cyclosporine prescriptions were estimated in the U.S. in 2024, covering nearly 1.19 million patients. The estimated number of U.S. cyclosporine users stood at around 1.25 million in 2023 before reaching approximately 1.19 million in 2024.

 

Major companies active in the market include Novartis AG, associated with Sandimmune and Neoral; AbbVie Inc., which supplies Gengraf; Viatris Inc., active in generic and specialty formulations; and Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd., which participate in generic cyclosporine products. Harrow, Inc. commercializes VEVYE® for dry eye disease, while Amneal Pharmaceuticals supplies generic ophthalmic cyclosporine formulations, including FDA-approved equivalents to Restasis. Santen Pharmaceutical focuses on ophthalmic cyclosporine therapies such as Verkazia.

 

Overall,the Cyclosporine Market is supported by its established role in organ transplantation, autoimmune disease treatment, dermatology, and ophthalmic care. A large existing prescription base, availability of branded and generic products, and participation from major global pharmaceutical companies provide a broad commercial foundation.

 

Leading Revenue Pools and Fastest-Growing Opportunities in the Cyclosporine Market

By Product Formulation

Leading Subsegment — Oral Cyclosporine

Oral Cyclosporine leads the product formulation segment with an estimated 49% market share, representing approximately USD 1.372 billion in 2025 revenue, and is projected to grow at a CAGR of 4.60% during 2026–2032. Its strong market position is supported by widespread use in preventing kidney, liver, and heart transplant rejection and treating severe rheumatoid arthritis and plaque psoriasis. Modified oral formulations, including microemulsion-based products, provide more predictable absorption, supporting sustained prescription demand and long-term cyclosporine therapy.

Fastest-Growing Subsegment — Ophthalmic Cyclosporine

Ophthalmic cyclosporine accounts for an estimated 35% of the Cyclosporine Market, representing approximately USD 0.980 billion in 2025 revenue, and is projected to expand at the fastest CAGR of 7.20% during 2026–2032. Its strong market position is supported by widespread use in chronic dry eye disease, where it reduces ocular surface inflammation and helps restore tear production. Key formulations, including Restasis, Cequa, and Vevye, further support market growth through differentiated concentrations, delivery systems, and improved ocular tolerability across major markets.

 

By Therapeutic Application

Leading Subsegment — Organ Transplantation

Organ transplantation represents the largest application segment in the Cyclosporine Market, accounting for an estimated 44% share and approximately USD 1.232 billion in 2025 revenue, with a projected CAGR of 4.50% during 2026–2032. Cyclosporine remains a key immunosuppressive therapy for preventing rejection after kidney, liver, heart, lung, and pancreas transplantation by suppressing T-cell activity and interleukin-2 production. Its continued use in combination immunosuppressive regimens sustains recurring demand, although nephrotoxicity, drug interactions, and therapeutic blood-level monitoring require careful clinical management.

Fastest-Growing Subsegment — Ophthalmic Disorders

Ophthalmic disorders account for an estimated 28% of the Cyclosporine Market, representing approximately USD 0.784 billion in 2025 revenue, and are projected to expand at the fastest CAGR of 7.10% during 2026–2032. Growth is supported by the established use of topical cyclosporine in chronic dry eye disease, where it reduces ocular surface inflammation and improves tear production. Commercial demand is reinforced by approved formulations such as Restasis, Cequa, and Vevye, along with broader specialist use across inflammatory ocular surface conditions.

 

By Brand Type

Leading and Fastest-Growing Subsegment — Generic Cyclosporine

Generic Cyclosporine leads and grow fastest the brand-type segment with an estimated 61% share, representing approximately USD 1.708 billion in 2025 revenue, and is projected to expand at a CAGR of 5.90% during 2026–2032. Its strong position in the Cyclosporine Market is supported by lower-cost alternatives to branded products such as Neoral, Gengraf, and Sandimmune. Generic formulations are widely used for transplant immunosuppression, rheumatoid arthritis, severe psoriasis, and chronic dry eye, supporting sustained prescription volumes across hospital, specialty, and ophthalmic care.

 

By Distribution Channel

Leading Subsegment — Hospital Pharmacies

Hospital pharmacies lead the cyclosporine market’s distribution-channel segment with an estimated 46% share, generating approximately USD 1.288 billion in 2025 revenue, and are projected to grow at a CAGR of 4.70% during 2026–2032. Their dominance reflects cyclosporine’s narrow therapeutic index, which requires close therapeutic drug monitoring, dose adjustment, and careful formulation management. Hospital pharmacists also help prevent inappropriate switching between modified and non-modified cyclosporine formulations, reducing risks of transplant rejection, nephrotoxicity, and unstable drug exposure.

Fastest-Growing Subsegment — Online Pharmacies

Online Pharmacies account for an estimated 16% share of the Cyclosporine Market, representing approximately USD 0.448 billion in 2025 revenue, and are projected to register the fastest CAGR of 7.00% during 2026–2032. Growth is supported by increasing digital access to chronic-use cyclosporine formulations, including ophthalmic products for dry eye and oral therapies for autoimmune conditions. Home delivery, automated refill services, prescription management, generic availability, and digital price comparison are improving medication accessibility and supporting recurring cyclosporine purchases through online pharmacy channels.

 

By Geography

Leading Subsegment — North America

North America leads the Cyclosporine Market with an estimated 38% share, representing approximately USD 1.064 billion in revenue in 2025, and is projected to expand at a CAGR of 4.90% during 2026–2032. Regional demand is supported by the established use of cyclosporine in kidney, liver, and heart transplantation, alongside treatment of psoriasis, rheumatoid arthritis, and severe dry eye disease. Continued adoption of microemulsion formulations with more predictable bioavailability further supports cyclosporine utilization across hospitals and specialty-care settings.

Fastest-Growing Subsegment — Asia-Pacific

Asia-Pacific accounts for an estimated 26% of the global Cyclosporine Market, representing approximately USD 0.728 billion in revenue in 2025, and is projected to record the fastest regional CAGR of 6.60% during 2026–2032. Cyclosporine adoption across the region is expanding rapidly across transplant prophylaxis, ophthalmology, and dermatology. Rising organ transplant procedures, increasing treatment of immune-mediated skin disorders, and wider use of cyclosporine-based ophthalmic therapies are strengthening prescription volumes and supporting sustained regional market expansion.

 

Competitive Landscape: Established Immunosuppressant Franchises and Ophthalmic Expansion Shape Cyclosporine Competition

Novartis AG — Established Systemic Cyclosporine Franchise Across Transplant and Autoimmune Care

Novartis holds one of the most established positions in systemic cyclosporine through its Neoral and Sandimmune franchises. Its current U.S. product portfolio includes Neoral cyclosporine modified soft-gelatin capsules and oral solution, along with Sandimmune cyclosporine capsules and injectable formulations. Neoral capsules are supplied in 25 mg and 100 mg strengths, while the oral solution contains 100 mg/mL of cyclosporine. Sandimmune is also available as 25 mg and 100 mg capsules, while its intravenous formulation contains 50 mg/mL cyclosporine.

The company's commercial relevance remains closely connected with transplantation. Sandimmune is indicated for the prevention of organ rejection in kidney, liver, and heart allogeneic transplantation, while Neoral also has applications in transplant recipients and selected patients with severe rheumatoid arthritis and psoriasis. The underlying treatment base remains substantial: the U.S. Health Resources and Services Administration reported more than 48,600 organ transplants in the United States during FY2025. Novartis therefore maintains exposure to a large recurring immunosuppressive treatment population rather than relying on a single cyclosporine indication.

AbbVie Inc. — Broad Presence Across Systemic and Ophthalmic Cyclosporine

AbbVie maintains an important position because its cyclosporine portfolio reaches both systemic immunosuppression and ophthalmic therapy. Gengraf is AbbVie's modified oral cyclosporine product for transplant and selected autoimmune applications. Current U.S. labeling includes 25 mg, 50 mg, and 100 mg capsules, while Gengraf Oral Solution is supplied at 100 mg/mL in a 50 mL bottle. Its prescribing information covers kidney, liver, and heart transplant recipients and also includes severe rheumatoid arthritis and psoriasis applications.

AbbVie also participates in ophthalmic cyclosporine through Restasis (cyclosporine ophthalmic emulsion 0.05%), which remains listed within AbbVie's current patient-support portfolio. Restasis established cyclosporine as a major prescription therapy for increasing tear production in patients with dry-eye-associated ocular inflammation. Competition increased materially when the FDA approved the first generic Restasis-equivalent cyclosporine ophthalmic emulsion 0.05% in February 2022, but AbbVie's combination of Restasis and Gengraf continues to give the company participation in both ophthalmic and systemic cyclosporine categories.

Other Major Companies and Their Roles in the Cyclosporine Market

• Harrow, Inc. — Ophthalmic Cyclosporine Commercialization: Harrow commercializes VEVYE 0.1% in the U.S. and Canada; VEVYE net sales increased from USD 28.06 million in 2024 to USD 88.69 million in 2025, providing one of the clearest current commercial growth signals in branded ophthalmic cyclosporine.

• Viatris Inc. — Complex Generic Ophthalmic Competition: Viatris subsidiary Mylan received the first FDA approval for a generic Restasis-equivalent cyclosporine ophthalmic emulsion 0.05% in February 2022, expanding generic competition in prescription dry-eye treatment.

• Sun Pharmaceutical Industries Ltd. — Differentiated Dry-Eye Formulation: Sun Pharma participates through CEQUA, a cyclosporine ophthalmic solution 0.09%; its Phase III confirmatory study included 744 patients, supporting the company's presence in branded dry-eye therapy.

• Teva Pharmaceutical Industries Ltd. — Oral Generic Cyclosporine Supplier: Teva markets modified cyclosporine capsules in 25 mg, 50 mg, and 100 mg strengths as well as a 100 mg/mL oral solution, providing generic alternatives to Neoral in systemic immunosuppressive therapy.

• Santen Pharmaceutical Co., Ltd. — Specialized Ophthalmic Cyclosporine: Santen's cyclosporine portfolio includes Verkazia, authorized in Europe for severe vernal keratoconjunctivitis in patients from 4 to 18 years of age, and Ikervis for severe keratitis associated with dry eye disease; Santen also launched Verkazia in China in December 2025.

• Amneal Pharmaceuticals, Inc. — New Generic Ophthalmic Entrant: Amneal received FDA approval in December 2025 for cyclosporine ophthalmic emulsion 0.05%, a generic equivalent of Restasis, with the company targeting commercial launch in Q1 2026, adding another competitor to the U.S. ophthalmic cyclosporine segment.

 

Analyst Commentary: Ophthalmic Innovation and Generic Competition Redefine Cyclosporine Growth

The Cyclosporine Market is shifting from a predominantly transplant-focused immunosuppressive category toward a broader therapeutic landscape that includes ophthalmology, autoimmune disease management, and specialized dermatological applications. The strongest growth opportunities are emerging in ophthalmic cyclosporine formulations, complex generics, improved drug-delivery systems, and wider treatment access across emerging healthcare markets. While organ transplantation continues to anchor the market's established revenue base, increasing competition in dry eye therapies and expanding generic availability are reshaping product positioning, pricing, and long-term growth opportunities.

 

Cyclosporine Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.80 Billion
Revenue Forecast in 2032	USD 4.04 Billion
Overall Growth Rate	CAGR of 5.30% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Product Formulation, By Therapeutic Application, By Brand Type, By Distribution Channel, By Geography
By Product Formulation	Oral Cyclosporine, Ophthalmic Cyclosporine, Injectable/Intravenous Cyclosporine
By Therapeutic Application	Organ Transplantation, Ophthalmic Disorders, Autoimmune Diseases, Psoriasis and Other Dermatological Applications
By Brand Type	Generic Cyclosporine, Branded Cyclosporine
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	A large existing prescription base, availability of branded and generic products, and participation from major global pharmaceutical companies provide a broad commercial foundation.
Customization Option	Available upon request